Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Valeant to buy Obagi Medical Products for $19.75 per share; Merz tops bid, offers $22 apiece; Valeant comes back offering $24

Executive Summary

Valeant Pharmaceuticals International Inc. continues to build its portfolio, this time through the acquisition of public dermatology-focused Obagi Medical Products Inc. Valeant will pay $19.75 per share (a 38% premium) in cash, valuing the transaction at $344.3mm.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies